Tools and Technology for a Better Life
Delray Beach, Florida USA (PRWEB) October 17, 2011
PositiveID Corporation (OTCBB: PSID), the parent company of the iGlucose™ system, is bringing the future technology of diabetes management to consumers now. The iglucose device connects with most major existing glucose meters (Glucometers) and transmits the data from the glucometer to a secure central database without the use or cost of any additional cellular network. Once the info is transmitted it can be shared with your choice of caregivers, healthcare professionals, and/or family members to help monitor and maintain logbooks and trend reports of blood glucose readings. This allows parents to checkup on their children or adult children to checkup on their parents to make sure they are doing the regular checks to prevent the occurrence of glucose values from reaching dangerous levels. The iglucose system also makes keeping the most import trends and records simple so that patterns can be recognized and crises averted through a simple viewing of electronically maintained records that are easy and simple for anyone to read.
The most important aspect of staying healthy with diabetes is to manage the glucose levels and keep them within a safe range. Monitoring the glucose levels on a regular basis and establishing patterns from daily behavior like eating allows people with diabetes to prevent and predict when glucose levels can become dangerous. The most effective way to do this is by regularly checking glucose levels and then maintaining records that can be analyzed to to determine what affects the person and how to correct it. For many people, keeping and maintaining these records several times daily and over long periods of time becomes unrealistic and puts treatment into chance. The iglucose system takes all the chance and work out of the process. Once an individual with diabetes does the required blood glucose check, iglucose does the rest. iglucose provides a lifelong, simple solution that is accessible and able to be shared with multiple designated parties.
The powerful and easy to use iglucose technology is designed to work with existing popular glucose meters already in the market and will be integrated to work in concert with a major breakthrough product in development and getting closer to coming to market from PositiveID – the company’s non-invasive (no pricks or blood required) breath-based glucose tester (glucometer) called Easy Check™. This revolutionary product will simply allow the user to blow into the device to get glucose readings. These readings could, of course, be transmitted with the iglucose system for the desired persons to read and monitor. The breath-based glucose meter is ready for pre-trial testing and is rapidly heading towards US Food and Drug Administration submission and entry into the marketplace.
For a detailed video presentation on the iglucose system you may click to view here:
PositiveID Corporation (OTCBB: PSID) develops unique medical devices and molecular diagnostic systems focused primarily on diabetes management, rapid medical testing and airborne bio-threat detection. Its wholly-owned subsidiary, MicroFluidic Systems or MFS, is focused on the development of microfluidic systems for the automated preparation of and performance of biological assays. PositiveID Corporation was formed on November 10, 2009 through the merger of VeriChip Corporation and Steel Vault Corporation.
In May 2011, PositiveID acquired California-based Microfluidic Systems, founded in 2001, which specializes in the development and production of automated instruments for detecting and processing of biological samples. MFS' core technology is used for airborne pathogen detection, rapid clinical diagnostics and sample preparation applications.
MFS' microfluidic technology alleviates all existing problems by replacing robotics with integrated microfluidics, reducing cost and increasing reliability. The company’s microfluidic technology also automates and increases the effectiveness of key sample processing steps used today on the laboratory bench-top, into a closed automated system. The embedded devices perform cell lysis (including difficult spores) in less than 1 minute at low power, nucleic acid purification along with inhibitor removal and pre-concentration of the nucleic acids up to factors of 1000X within minutes. These processes all occur autonomously within a fully contained disposable microfluidic cartridge.
PositiveID operates in two main divisions: HealthID and SecurityID. The HealthID segment develops unique medical devices, focused primarily on diabetes management, and rapid medical testing applications. Its SecurityID segment develops airborne bio-threat detection systems.
An integral part of the history of PositiveID is its radio-frequency identification (RFID) implantable microchip for patient identification, the VeriChip. The company's RFID microchip traces back to the events of September 11, 2001, when New York firemen wrote their badge ID numbers on their chests in case they were found injured or unconscious. It was evident there was a serious need for personal information in emergency situations and the product, modeled after a similar microchip used in pets, evolved from there. The company received FDA clearance for the microchip in October 2004.
For more information or an interview with PositiveID Corporation (OTCBB: PSID) please email or call for scheduling:
Sr. VP, Investor Relations & Corporate Communications
PositiveID Corporation (OTCBB: PSID.)
Safe Harbor Statement
Statements about PositiveID’s future expectations, including the likelihood that PositiveID is bringing the future technology of diabetes management to consumers now; the likelihood that iglucose allows parents to check up on their children or adult children to check up on their parents to make sure they are doing the regular checks to prevent glucose values from reaching dangerous levels; the likelihood that the iglucose system also makes keeping the most import trends and records simple so that patterns can be recognized and crises averted through a simple viewing of electronically maintained records that are easy and simple for anyone to read; the likelihood that the iglucose system takes all the chance and work out of the diabetes management process; the likelihood that iglucose provides a lifelong, simple solution that is accessible and able to be shared with multiple designated parties; the likelihood that iglucose will be integrated to work in concert with a major breakthrough product in development and getting closer to coming to market from PositiveID – the company’s non-invasive (no pricks or blood required) breath-based glucose tester called Easy Check™; the likelihood that Easy Check will simply allow the user to blow into the device to get glucose readings; the likelihood these readings could be transmitted with the iglucose system for the desired persons to read and monitor; the likelihood the breath-based glucose meter is ready for pre-trial testing and is rapidly heading towards U.S. Food and Drug Administration submission and entry into the marketplace; and all other statements in this release other than historical facts are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID’s actual results could differ materially from expected results. These risks and uncertainties include PositiveID’s ability to successfully develop and commercialize its iglucose system and Easy Check device; as well as certain other risks. Additional information about these and other factors that could affect the Company’s business is set forth in the Company’s various filings with the Securities and Exchange Commission, including those set forth in the Company’s 10-K filed on March 25, 2011, and 10-Qs filed on May 13, 2011, and August 15, 2011, under the caption “Risk Factors.” The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.
Analysts’ Compensation: Mass Media 77, Inc. who in part or in whole may be responsible for the preparation of this report may receive compensation based various factors, including the quality and accuracy of research, client feedback, competitive factors, and overall firm revenues, which include revenues from, among other business units, Institutional Equities and Investment Banking and restricted stock.
Information has been obtained from sources believed to be reliable but Mass Media 77, Inc or its affiliates and/or subsidiaries (collectively Mass Media 77, Inc.) do not warrant its completeness or accuracy. Opinions and estimates constitute our judgment as of the date of this material and are subject to change without notice. Past performance is not indicative of future results. This material is not intended as an offer or solicitation for the purchase or sale of any financial instrument. The opinions and recommendations herein do not take into account individual client circumstances, objectives, or needs and are not intended as recommendations of particular securities, financial instruments or strategies to particular clients. The recipient of this report must make its own independent decisions regarding any securities or financial instruments mentioned herein. Periodic updates may be provided on companies/industries based on company specific developments or announcements, market conditions or any other publicly available information. Additional information may be available upon request.
# # #